Johnson & Johnson (JNJ)
Why PG, JNJ, and KO Could Surprise Investors Next Year
Defensive blue chips rarely dominate headlines, but heading into 2027, three of the market's most reliable dividend payers stand out as durable compounders.
Johnson & Johnson (JNJ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
5 Dividend Stocks Every Boomer Should Own Heading Into Fall
Boomers heading into Fall 2026 are doing what disciplined income investors always do in August: rotating away from summer growth chasers and locking in reliable Q3 and Q4 cash flow.
Johnson & Johnson (JNJ) Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System Transcript
Johnson & Johnson (JNJ) Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System Transcript
J&J's Strong Q2 Oncology Performance Fuels Future Growth Hopes
J&J's oncology business posted strong Q2 growth as Darzalex, Erleada and newer cancer drugs boosted sales and advanced its long-term ambitions.
Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Johnson & Johnson's OTTAVA Robotic Surgery System Targets Long-Term Growth
Johnson & Johnson NYSE: JNJ outlined its commercialization plans for the OTTAVA robotic surgical system after receiving U.S. Food and Drug Administration De Novo authorization, positioning the table-integrated platform as a long-term growth initiative in surgical robotics.
3 Dividend Stocks to Buy Before August Ends and Hold Forever
August has a habit of humbling investors. The VIX sits at 17.09, well off the March 2026 peak of 31.05, but the pattern is familiar: quiet summer tape, thin liquidity, and a single headline that can send correlations to one.
Johnson & Johnson (JNJ) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines
Under the agreement, Johnson & Johnson would make total initial payments of $785 million, and has the exclusive option to acquire Sail for $2.58 billion.
Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer
Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer.
Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits
Johnson & Johnson says it will pay an estimated $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and talc caused ovarian cancer.
